Market Insight - Reforms set to knock Chinese pharma market into shape
This article was originally published in Scrip
The Chinese government's substantial investment in healthcare reform and the creation of a more innovative and competitive local industry will greatly affect the key players in this fast-growing market. Chee Hew and Jennifer Matheny suggest what innovative, manufacturing and distribution companies can do to keep up.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.